Pre-Test Understanding the Presentation, Diagnosis, and Risk Stratification of Myelofibrosis, Polycythemia Vera, and Essential Thrombocytopenia Pre-Test 1. Which of the following is a selective inhibitor of JAK1, JAK2, and ACVR1 and was developed for use in anemic MF patients? A. Fedratinib B. Momelotinib C. Parsaclisib D. Ruxolitinib E. Unsure 2. According to 5-year follow-up data from the phase 3 RESPONSE study, which of the following agents was shown to be a safe and effective long-term treatment option for patients with polycythemia vera who are resistant to or intolerant of best available therapy (ie, hydroxyurea)? A. Anagrelide B. Momelotinib C. Pacritinib D. Ruxolitinib E. Unsure 3. Which of the following are considered driver events in MPNs? A. JAK2, CALR, and MPL B. JAK2, ASXL1, and U2AF1 C. JAK2, CALR, and SRSF2 D. JAK2, ASXL1, and CALR E. Unsure 4. The phase 3 PERSIST-2 trial evaluated __________ versus best available treatment and found that a spleen volume reduction of 35% was achieved in significantly more patients treated with this therapeutic as compared with best available therapy. A. Fedratinib B. Pacritinib C. Parsaclisib D. Ruxolitinib E. unsure 5. How confident are you in your ability to use integrated strategies to promptly identify, manage, monitor, and mitigate treatment-related adverse events associated with MF, PV and/or ET? Very Confident Confident Somewhat Confident Not very confident Not at all confident
